A Systematic Literature Review and Meta-Analysis of Radioimmunotherapy Consolidation for Patients With Untreated Follicular Lymphoma

Rose, Adam C.; Shenoy, Pareen J.; Garrett, Gia; Seward, Miray; Kucuk, Roy A.; Doksansky, Hannah; Nastoupil, Loretta J.; Flowers, Christopher R.

doi:10.1016/j.clml.2012.09.012

Cited by 13 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of the combined regimen of rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R‐CHOP) had been the most spread used schedule of therapy, but other schemes have been raising like rituximab–bendamustine and so on ; at the same time, consolidation and maintenance approaches like rituximab maintenance every 8 wk during 2 yr or consolidation with radioimmunotherapy (RIT) with 90‐yttrium‐ibritumomab‐tiuxetan (ZEVALIN ® ; Spectrum Pharmaceuticals. Henderson, NV) had decreased the rate of relapses improving the time free of therapy .…”

mentioning

confidence: 99%

Long‐term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90‐yttrium‐ibritumomab‐tiuxetan

Andrade‐Campos

Liévano

Espinosa-Lara

et al. 2016

European J of Haematology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Long‐term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90‐yttrium‐ibritumomab‐tiuxetan

Andrade‐Campos

Liévano

Espinosa-Lara

et al. 2016

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…De nombreux autres essais cliniques ont déjà eu lieu et sont encore en cours pour tester l'efficacité de la RITβ dans le traitement de cancers hématologiques [9][10][11] et de cancers métastatiques [12][13][14].…”

Section: Revuesunclassified

Radio-immunothérapie alpha

Ménager¹,

Gorin²,

Fichou³

et al. 2016

Med Sci (Paris)

View full text Add to dashboard Cite

> La radioimmunothérapie alpha (RITα) est une thérapie anticancéreuse vectorisée utilisant généralement un anticorps monoclonal spécifique d'un antigène tumoral couplé à un émetteur de particules α. Les émetteurs α représentent un outil idéal pour éradiquer les tumeurs disséminées ou les métastases. De récentes données démontrent que les rayonnements ionisants, en plus de leur cytotoxicité directe, peuvent aussi induire une immunité antitumorale efficace. Les effets biologiques de l'irradiation pourraient donc être utilisés pour potentialiser la réponse à différents types d'immunothérapie, et ainsi ouvrir la voie au développement de nouvelles thérapies combinant RITα et immunothérapies. < radionucléide. Le choix du radionucléide repose sur des considérations pratiques (le coût, la disponibilité, le type de techniques de radiomarquage et la facilité d'utilisation), le type d'émission du radioélément, le transfert d'énergie linéique (TEL : quantité d'énergie transférée au milieu par la particule incidente, par unité de longueur de la trajectoire en keV 1 /µm) et la demi-vie physique du radioisotope (durée nécessaire pour que la moitié des noyaux radioactifs d'une source se soient désintégrés) [2]. Cette dernière doit être, autant que possible, en adéquation avec la pharmacocinétique du vecteur utilisé, afin de délivrer la plus grande dose possible de radioactivité à la tumeur après l'injection. Une demi-vie trop courte entraînera un nombre élevé de désintégrations avant d'atteindre la cible. À l'inverse, une demi-vie trop longue engendrera un grand nombre de désintégrations du radionucléide pendant la phase d'éli-mination du vecteur, rendant le radioimmunoconjugué plus toxique. La demi-vie doit également être compatible avec les applications cliniques et la prise en charge du patient. Ainsi, le temps nécessaire au transfert du radionucléide du site de production jusqu'à l'hôpital, 1 1 keV (kiloélectronvolts) = 10 3 eV ; 1 MeV (megaélectonvolts) = 10 6 eV.

show abstract

“…In addition to being approved by the FDA for use in patients with metastatic colorectal cancer, bevacizumab is approved for patients with unresectable or recurrent non-squamous non-small cell lung carcinoma. It is also being tested in clinical trials for the treatment of a number of other tumor types 10,11 .…”

Section: Inhibition Of Angiogenesismentioning

confidence: 99%

Untitled

2015

IJPSR

View full text Add to dashboard Cite

Developing innovative delivery strategies remains an ongoing task to improve both efficacy and safety of drug-based therapy. Anti-cancer drug treatment is seriously affected by various undesirable properties such as poor solubility, narrow therapeutic index and efflux transporter specificity. One of the primary aspects of a successful cancer treatment regimen is to deliver sufficient amounts of drug to tumors while minimizing damage to normal tissues. In this review we highlight the development of promising recent innovative approaches that will hopefully offer not only gains in efficacy, but also in safety, tolerability and convenience in the treatment of patients with cancer. Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery for cancer. Cancer drug delivery is no longer simply wrapping up cancer drugs in a new formulation for different routes of delivery. The focus is on targeted cancer therapy. The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent damage to normal tissues and prevent drug resistance. Innovative cancer therapies are based on current concepts of molecular biology of cancer. These include antiangiogenic agents, immunotherapy, bacterial agents, viral oncolysis, targeting of cyclic-dependent kinases and tyrosine kinase receptors, antisense approaches, gene therapy and combination of various methods. Important methods of immunotherapy in cancer involve use of cytokines, monoclonal antibodies, cancer vaccines and immunogene therapy. Introduction: Innovative treatment approaches to diseases are revolutionizing clinical paradigms with the aim of providing therapy tailored not only to the individual and disease but also within disease sub-types. One of the primary goals of a successful cancer treatment regimen is to deliver sufficient amounts of drug to tumors while minimizing damage to normal tissues.

show abstract

A Systematic Literature Review and Meta-Analysis of Radioimmunotherapy Consolidation for Patients With Untreated Follicular Lymphoma

Cited by 13 publications

References 24 publications

Long‐term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90‐yttrium‐ibritumomab‐tiuxetan

Long‐term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90‐yttrium‐ibritumomab‐tiuxetan

Radio-immunothérapie alpha

Untitled

Contact Info

Product

Resources

About